Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Parallel-controlled Phase II Study of Toripalimab Combined With CAV/IE Regimen Versus Chemotherapy Alone in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcoma Who Have Failed Standard Treatment

Next Previous
Trial Profile

A Multicenter, Randomized, Parallel-controlled Phase II Study of Toripalimab Combined With CAV/IE Regimen Versus Chemotherapy Alone in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcoma Who Have Failed Standard Treatment

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Toripalimab (Primary) ; Vincristine (Primary)
  • Indications Cancer metastases; Chondrosarcoma; Clear cell sarcoma; Dermatofibrosarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Nerve sheath neoplasms; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Jun 2026 Planned number of patients changed from 200 to 134.
  • 12 Jun 2026 Planned End Date changed from 30 Jun 2026 to 30 Jun 2027.
  • 12 Jun 2026 Planned primary completion date changed from 30 Jan 2025 to 30 Jan 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top